What is GALT stock price today?

GALT (Galectin Therapeutics Inc) stock is trading at $2.56 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GALT stock going up or down today?

GALT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GALT stock now?

The decision to buy GALT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GALT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GALT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GALT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if GALT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is GALT's P/E ratio?

P/E ratio data for GALT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is GALT's market cap?

GALT (Galectin Therapeutics Inc) has a market capitalization of $0.16 billion, making it a small-cap stock.

What is GALT's price to book ratio?

GALT trades at a price-to-book (P/B) ratio of 207.70, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GALT pay dividends?

GALT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is GALT's dividend yield?

GALT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is GALT stock a good long-term investment?

GALT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GALT's revenue growth rate?

Revenue growth data for GALT is available on our dashboard with detailed financial statement analysis.

Profitability metrics for GALT are available on our dashboard with complete income statement analysis.

What are the risks of investing in GALT?

Key risks for GALT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GALT compare to its competitors?

Compare GALT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GALT's performance and positioning.

What is GALT's stock price target for 2026?

Our AI model provides price targets for GALT based on fundamental analysis: Bull case $3.33 (+30%), Base case $2.94 (+15%), Bear case $2.30 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GALT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GALT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GALT's next earnings report?

GALT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GALT - Galectin Therapeutics Inc

NYSE * Health Care * Biotechnology

$2.56

+$0.09 (+3.64%)

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Key Statistics

Market Cap

$162.59M

P/B Ratio

207.70

EPS

$-0.48

Employees

How GALT Compares to Peers

GALT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
GALT(This stock)	$162.59M	N/A	0%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Galectin Therapeutics Inc Company Information

Headquarters: Georgia; U.S.A
Website: galectintherapeutics.com
Sector: Health Care
Industry: Biotechnology

GALT - Galectin Therapeutics Inc

About Galectin Therapeutics Inc

GALT Key Statistics

How GALT Compares to Peers

Galectin Therapeutics Inc Company Information

GALT Lician Score

GALT Financial Snowflake

Upcoming Events for GALT